Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
FAIL · Does not pass the screen
256.82 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price256.82 USD at the 6 Nov 2026 close
Our value readFair vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.49, read 2026-11-08
Ethical does not pass the values gate
Price256.82 USD
Fair value262.24
Ethical score70.0/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-10-27Read Accumulation242.99+5.7% to today ✓Markdown gives way to Accumulation after a 7% rise in 7 days
2026-10-20Read Markdown226.62+13.3% to today Distribution gives way to Markdown
2026-09-24Read Distribution237.59+8.1% to today Accumulation gives way to Distribution
2026-08-22Read Accumulation246.23+4.3% to today ✓Distribution gives way to Accumulation after a 13% rise in 7 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ascendis Pharma A/S holds its Accumulation at $256.82. Consolidating, no directional conviction, held for 60 days.
As held on the ledger · 2026-11-06
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 60 days
Price at the screen
$256.82
Valuation
19.42 trailing · 25.36 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
66.93%
Below 33%
Interest-bearing debt is 66.9% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
58.14%
Below 49%
Money owed to the company is 58.1% of assets, above the 49% limit.
Fail
Revenue purity
2.12%
Below 5%
Only 2.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Ascendis Pharma A/S's business is in a permissible area, but its interest-bearing debt is about 67% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ASND's ethical verdict changes
Today ASND does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades at roughly a 2% discount to our $262.24 fair value, narrow competitive moat, 114.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 2.1% discount to the base estimate.
Third-party analyst targets: 21 covering, consensus Strong Buy. The average target sits +19% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $262.24, with a range of $236.18 to $301.58, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Strong biotech metrics but almost no safety margin
A young patient in need of steady growth hormone therapy rarely thinks about the complex delivery platform behind the medicine. Ascendis stands out for its 144 percent revenue growth, 57 percent profit margin and 333 percent return on equity, yet the narrow moat and two percent margin of safety at the current price leave almost no room for error.
Forward earnings sit at a reasonable 24.8 times, and analysts see further upside, but the opportunity rating remains none because the numbers already reflect most of that promise. Ethical screens are cleared without issue.
Risk sits with clinical setbacks or competition that could quickly erode the premium valuation. Currency moves and execution in new indications add further volatility for a business still scaling. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Denmark and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ASND trades on NASDAQ (the company is based in Denmark). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Accumulation$251.27+3.4%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $293.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $293.
2026-10-20Markdown · changed$226.62-1.1%Entry 9
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $293.
2026-10-13Distribution$229.23-3.5%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $293.
2026-10-02Distribution$237.59+0.0%Entry 7
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $293.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $293. Since the last review it its composite score rose.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $293.
2026-07-21Distribution$261.00+19.7%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 19.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $293.
2026-07-18Distribution$218.06+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $293.
2026-07-03Distribution$218.06+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
